Oxaliplatin during radiotherapy — Competitive Intelligence Brief

Oxaliplatin during radiotherapy (Oxaliplatin during radiotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy agent. Area: Oncology.

phase 3 Platinum-based chemotherapy agent DNA Oncology Small molecule

Target snapshot

Oxaliplatin during radiotherapy (Oxaliplatin during radiotherapy) — Universitätsmedizin Mannheim. Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxaliplatin during radiotherapy TARGET	Oxaliplatin during radiotherapy	Universitätsmedizin Mannheim	phase 3	Platinum-based chemotherapy agent	DNA
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-05-14 — Vidaza · 12053482 · Method of Use · US
• 2029-05-14 — Vidaza · 11571436 · Formulation · US
• 2030-06-03 — Vidaza · 8846628 · Formulation · US

Sponsor landscape (Platinum-based chemotherapy agent class)

1. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 3 drugs in this class
2. Merck Sharp & Dohme LLC · 2 drugs in this class
3. Federation Francophone de Cancerologie Digestive · 2 drugs in this class
4. Sun Yat-sen University · 2 drugs in this class
5. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
6. Chinese Academy of Medical Sciences · 1 drug in this class
7. Biocad · 1 drug in this class
8. Gruppo Oncologico Italiano di Ricerca Clinica · 1 drug in this class
9. Celgene · 1 drug in this class
10. Gao-jun Teng · 1 drug in this class